ESPR - Esperion Therapeutics Inc Volatility & Greeks
This article provides a detailed financial overview of Esperion Therapeutics Inc (ESPR), including its stock performance, market capitalization, income, sales, and various financial ratios. It also lists insider and institutional ownership, short interest, and volatility metrics, alongside analyst recommendations and target prices. The data aims to offer a comprehensive snapshot of the company's financial health and market position.
Esperion Therapeutics focuses on cholesterol treatments as investors watch long-term growth
Esperion Therapeutics, a biopharmaceutical company, centers its strategy on developing oral non-statin cholesterol therapies for patients who cannot tolerate statins or need additional lipid-lowering support. The company aims to differentiate itself by offering an oral alternative in a market dominated by statins and injectable therapies, focusing on treatments that reduce LDL-C and cardiovascular events. Investors are watching the company's ability to secure regulatory approvals, navigate market competition, and expand patient adoption, with stock performance reflecting its success in translating scientific expertise into commercial traction.
10 Health Care Stocks With Whale Alerts In Today’s Session
This article identifies 10 healthcare stocks that showed "whale alerts" in their options trading activity during today's session, indicating significant movements by large-volume traders. It details specific call and put options with varying sentiments (bearish, bullish, neutral) for companies like Esperion Therapeutics, Revolution Medicines, and Tenet Healthcare, providing strike prices, expiration dates, and total trade prices. The alerts are based on options activity that diverges from normal worth, suggesting potential trading opportunities.
Enterprise value to revenue forward of Esperion Therapeutics, Inc. – NASDAQ:ESPR
This article provides financial information for Esperion Therapeutics, Inc. (ESPR) on TradingView, focusing on its enterprise value to forward revenue. It highlights the company's stock market presence on Nasdaq within the pharmaceuticals sector, offering an overview of its financials and market data.
Price to earnings forward of Esperion Therapeutics, Inc. – NASDAQ:ESPR
The article focuses on the "Price to earnings forward" metric for Esperion Therapeutics, Inc. (NASDAQ: ESPR). It briefly presents this specific financial data point within a larger financial platform context, implying it's a key piece of information for investors. However, no actual financial figures are provided in the content.
Esperion Therapeutics, Inc. Actuals & Estimates (DUS:0ET)
This article provides an overview of Esperion Therapeutics, Inc. (0ET) on the Dusseldorf Stock Exchange, including its financial actuals and analyst estimates. It covers key financial metrics like earnings, revenue, net income, and EBITDA, as well as stock performance data and an upcoming earnings release date. The article also addresses frequently asked questions regarding the company's stock ticker, future price forecasts, historical highs and lows, and dividend policy.
Esperion Therapeutics Inc (ESPR) Institutional Confidence
Esperion Therapeutics Inc (ESPR) has an institutional shareholding score of 5.00, ranking 73rd out of 157 in the Pharmaceuticals industry. Institutional shareholding has increased by 2.95% quarter-over-quarter, now standing at 66.50%. Chuck Royce is the largest institutional shareholder, holding 2.30M shares, representing 1.02% of shares outstanding.
Esperion Therapeutics (ESPR) Stock Fair Value Moves Lower After Analyst Downgrades
Esperion Therapeutics (ESPR) has seen its fair value estimate significantly downgraded by analysts, moving from approximately US$6.50 to US$3.19 per share, a 51% reduction. This adjustment reflects a more cautious stance from several investment firms regarding the company's execution on growth plans and potential revenue. The revised targets incorporate changes in revenue growth assumptions, net profit margin forecasts, and future P/E multiples, indicating a tighter valuation framework for the company.
Esperion Therapeutics (ESPR) Proxy filing Summary
Esperion Therapeutics (ESPR) has entered a definitive agreement to be acquired by ARCHIMED for $3.16 per share in cash, with potential milestone payments up to $100 million. The transaction is expected to close in Q3 2026, pending regulatory and shareholder approval. Shareholders will vote on the merger, which the Board recommends approving.
Esperion (ESPR) CEO sells shares to cover RSU taxes, retains 2.12M
Esperion Therapeutics, Inc. President and CEO Sheldon L. Koenig sold 53,588 shares of common stock at $3.155 per share. This transaction was conducted to satisfy tax obligations related to vested restricted stock units, a common practice in equity compensation. Following the sale, Koenig retains a substantial direct holding of 2,119,111 shares, indicating the sale was for tax purposes rather than a reduction in his overall confidence in the company.
Esperion (NASDAQ: ESPR) CFO sells shares to pay taxes on vested RSUs
Esperion Therapeutics' CFO, Benjamin Halladay, sold 10,773 shares of common stock at $3.155 per share to cover tax obligations from vested restricted stock units. This transaction, filed on a Form 4, indicates a net sale of $33,989 but Halladay still retains a substantial direct holding of 702,829 shares in the company. Such sales are described as routine tax-related events rather than discretionary portfolio decisions.
Esperion (NASDAQ: ESPR) details Corstasis acquisition cost, debt and royalty financing
Esperion Therapeutics (NASDAQ: ESPR) has filed an amended 8-K report detailing the financial aspects of its acquisition of Corstasis Therapeutics, which closed on April 2, 2026. The acquisition, treated as an asset acquisition, cost $83.389 million, primarily allocated to the acquired product Enbumyst, and was funded by a $25.0 million term loan and a $50.0 million royalty sale. Pro forma financials for 2025 show that the acquisition widened Esperion's net loss from $22.682 million to $47.063 million, primarily due to amortization and increased financing costs.
Esperion (NASDAQ: ESPR) CLO trims 11,824 shares to pay RSU taxes
Esperion Therapeutics' Chief Legal Officer, Benjamin Looker, sold 11,824 shares of common stock at an average price of $3.155 per share. This transaction was conducted to cover tax obligations arising from recently vested restricted stock units (RSUs). Following the sale, Mr. Looker still retains a direct holding of 667,524 shares in the company.
ESPR insider sale notice: 53,588 shares tied to vesting (ESPR)
Esperion Therapeutics (ESPR) filed a Form 144 notice indicating 53,588 shares of common stock are listed for sale, tied to restricted stock vesting on June 16, 2026, and designated as compensation. This filing enables the resale of these shares under Section 144 procedures. The notice also reveals a prior sale of 25,578 shares on March 17, 2026, for $69,551.70 by Sheldon Koenig.
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Esperion Therapeutics, Inc. (NasdaqGM: ESPR) to ARCHIMED-managed funds. The law firm is evaluating whether the consideration of $3.16 cash per share plus contingent milestone payments is adequate and whether the process leading to the proposed sale was fair to shareholders. KSF encourages shareholders who believe the transaction undervalues the company to contact them.
Benjamin Halladay to sell 10,773 ESPR shares after vesting (ESPR)
Benjamin Halladay has filed a Form 144 to report the intended resale of 10,773 shares of Esperion Therapeutics (ESPR) common stock, which vested on June 15, 2026. The filing also disclosed a previous sale of 6,424 shares on March 17, 2026. This administrative disclosure is a routine notice for vested restricted shares and is considered to have a neutral impact on the market.
Esperion Therapeutics Inc (ESPR) Valuation: PE, PB & Fair Value Analysis
Esperion Therapeutics Inc (ESPR) has a current valuation score of 9.46, placing it 20th within the Pharmaceuticals industry. The company's P/E ratio is -1022.65, significantly below its recent high. Other key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed.
Esperion Therapeutics Inc (ESPR) Financial Health: Profitability & Balance Sheet Analysis
Esperion Therapeutics Inc (ESPR) currently holds a stable financial score of 8.30, placing it 69th out of 157 in the Pharmaceuticals industry. The company reported a significant year-over-year revenue increase of 23.25% to $80.10M and a net profit increase of 37.72%, indicating high operating efficiency. Despite its strong performance, several detailed financial metrics are yet to be disclosed by the company.
Esperion Therapeutics Inc (ESPR) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Esperion Therapeutics Inc (ESPR), focusing on its support and resistance levels, key indicators, and moving averages. According to the analysis, ESPR's stock price is currently trading within a range of $3.13 to $3.18, making it suitable for range-bound swing trading. Technical indicators show a mixed signal with 2 buy and 1 sell signals, while moving averages suggest a strong buy signal across various periods.
Esperion Therapeutics (ESPR) Q1 2026 earnings summary
Esperion Therapeutics (ESPR) reported a Q1 2026 net loss of $25.2 million, an improvement from Q1 2025, driven by increased product sales and collaboration revenues and reduced R&D expenses. The company also completed the acquisition of Corstasis, adding Enbumyst to its portfolio, and entered a definitive merger agreement to be acquired by Essence Parent Inc. The merger is expected to finalize in Q3 2026, subject to approvals.
Esperion (NASDAQ: ESPR) gains HSR clearance ahead merger vote
Esperion Therapeutics (NASDAQ: ESPR) has secured Hart-Scott-Rodino (HSR) antitrust clearance for its merger with Essence Parent Inc., an affiliate of ArchiMed SAS, with the waiting period expiring on June 15, 2026. This removes a significant regulatory hurdle, though the merger's completion still hinges on other conditions, most notably stockholder approval. Esperion has scheduled a virtual special meeting for July 8, 2026, for stockholders to vote on the proposed acquisition.
Esperion Therapeutics Inc. (ESPR) News, Articles, Events & Latest Updates
Esperion Therapeutics (ESPR) has seen recent significant activity, with its stock surging nearly 44% in a month due to an acquisition agreement by Archimed for up to $1.1 billion. The deal involves $3.16 cash per share plus potential milestone payments. This has led to multiple shareholder alerts and legal inquiries regarding the fairness of the merger and its terms for shareholders.
German antitrust clears Esperion (ESPR) merger with ArchiMed affiliate Essence Parent
Esperion Therapeutics announced that Germany's competition authority has approved its planned merger with Essence Parent Inc., an affiliate of ArchiMed SAS. This clearance satisfies a key regulatory condition for the merger, which still requires approvals under the U.S. Hart-Scott-Rodino Act and Esperion stockholder approval at a virtual special meeting on July 8, 2026. The merger would result in Esperion becoming a wholly-owned subsidiary of Essence Parent Inc.
Glazer Capital (ESPR) reports 20,975,620 shares, an 8.15% position
Glazer Capital, LLC and Paul J. Glazer have disclosed an 8.15% passive stake in Esperion Therapeutics, Inc. (ESPR), holding 20,975,620 shares. This information was reported in a Schedule 13G filing with the SEC, indicating shared voting and dispositive power over the shares managed by Glazer-managed funds. The filing specifies that Glazer Capital Enhanced Master Fund, Ltd. has the right to receive proceeds from the sale of these securities.
ESPR Stock Falls After Esperion’s Mixed Q4 — Retail Remains Unfazed, Eyes ‘Massive’ Upcoming Catalysts
Esperion Therapeutics (ESPR) shares dropped over 6% after reporting mixed Q4 earnings, with EPS below expectations but revenue slightly above. Despite the stock's fall, retail investors on Stocktwits remained highly bullish, citing future catalysts like U.S. market expansion, progress on a triple-combination program, and the acquisition of Corstasis Therapeutics. The company's CEO emphasized a long-term strategy for growth and value creation.
Esperion (NASDAQ: ESPR) director receives 79,873-share stock grant
Esperion Therapeutics director Robert E. Hoffman received a grant of 79,873 shares of common stock as a compensation award, bringing his direct holdings to 85,153 shares. The shares were granted at $0.00 per share and will vest in full on the earlier of May 28, 2027, or Esperion's next annual meeting of stockholders following May 28, 2026. This transaction reflects equity-based compensation rather than an open-market purchase.
Director at Esperion Therapeutics (ESPR) receives 79,873-share equity award
J. Martin Carroll, a director at Esperion Therapeutics (ESPR), received an equity award of 79,873 shares of common stock at no cash cost. This grant, which increases his direct holdings to 177,523 shares, will fully vest on the earlier of May 28, 2027, or the company’s next annual meeting after May 28, 2026. This transaction was reported in a Form 4 filing, indicating a compensation-related acquisition under transaction code A.
Esperion Therapeutics, Inc. 8-K Filing Details for May 28, 2026: Company Information, NASDAQ Listing, and Stock Option Plan Amendments
Esperion Therapeutics, Inc. (NASDAQ: ESPR) filed an 8-K report on May 28, 2026, detailing the results of its Annual Meeting of Stockholders. Key outcomes included the election of Class I directors, approval of executive compensation, ratification of Ernst & Young LLP as auditor, and a significant amendment to the 2022 Stock Option & Incentive Plan, increasing authorized shares by 7,000,000. This amendment, which brings the total maximum shares to 30,150,000, could lead to dilution for existing shareholders but also signals the company's intent to retain and attract talent or support growth initiatives.
Esperion (NASDAQ: ESPR) director receives 79,873-share stock award grant
Esperion Therapeutics director John Craig Thompson has received a grant of 79,873 shares of common stock as compensation. The award has a reported price of $0.00 per share and will vest in full either on May 28, 2027, or the company's next annual meeting of stockholders following May 28, 2026, whichever comes first. This transaction is classified as an equity compensation grant, not an open-market purchase.
Esperion (NASDAQ: ESPR) investors approve 7M-share plan boost and board slate
Esperion Therapeutics, Inc. stockholders approved all proposals at their 2026 annual meeting, including an amendment to increase authorized shares under the 2022 Stock Option and Incentive Plan by 7,000,000. They also elected two Class I directors, J. Martin Carroll and Sheldon L. Koenig, ratified Ernst & Young LLP as the independent registered public accounting firm, and approved the advisory vote on executive compensation. A quorum was established with 177,208,856 shares represented out of 257,404,876 outstanding shares.
Esperion Therapeutics (ESPR) director receives 79,873-share stock award
Esperion Therapeutics director Jay Shepard was granted 79,873 shares of Common Stock as a stock award with no purchase price, increasing his direct holdings to 164,472 shares. The shares will vest fully on the earlier of May 28, 2027, or the company’s next annual meeting after May 28, 2026, linking vesting to his future board service. This transaction is classified as compensation-related share acquisition rather than a market purchase or sale.
Trial tests cholesterol drug in kids with inherited high cholesterol
Esperion (NASDAQ: ESPR) presented new data at the European Atherosclerosis Society Congress 2026 for its cholesterol drug, bempedoic acid. A Phase 2 pediatric study for children aged 6-17 with heterozygous familial hypercholesterolemia demonstrated LDL-C reductions of 6-25% with no new safety concerns. Additionally, a post hoc analysis of the CLEAR Outcomes study in statin-intolerant adults indicated that 42% of patients achieved a >=30% LDL-C reduction, with female sex, higher baseline LDL-C, and concurrent ezetimibe use being positive factors.
Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026
Esperion announced new data from a Phase 2 pediatric study of bempedoic acid and a post hoc analysis from the CLEAR Outcomes study at the European Atherosclerosis Society Congress 2026. The pediatric study showed bempedoic acid lowered LDL-C and was well tolerated in children aged 6-17 with familial hypercholesterolemia. The CLEAR Outcomes analysis identified patient factors, such as female sex, higher baseline LDL-C, and concurrent ezetimibe use, associated with a 30% or greater reduction in LDL-C in statin-intolerant adults.
Esperion Therapeutics stock (US2964331002): buyout by Archimed and fresh earnings put focus on futur
Esperion Therapeutics is being acquired by healthcare investor Archimed in a deal valued at up to $1.1 billion following the biotech's latest quarterly earnings report. This acquisition puts the Nasdaq-listed cholesterol specialist back on investors' radar, combining an M&A story with financial results. The deal highlights the strategic rationale for Archimed to accelerate growth through operational support and capital, potentially increasing flexibility for Esperion without public market pressures.
ETFs Investing in Esperion Therapeutics, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of Esperion Therapeutics, Inc. (0ET). The list, sorted by market value, includes details such as issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, and 3-year total return for each ETF. The ETFs primarily include small-cap, health care, and biotech funds from major issuers like BlackRock, State Street, and Vanguard.
Esperion Therapeutics (ESPR) price target decreased by 59.91% to 2.97
This article reports that the price target for Esperion Therapeutics (ESPR) has been significantly decreased by 59.91% to $2.97. No further details regarding the reason for this reduction or the analyst who made the change are available in the provided content.
Esperion Therapeutics estimates U.S. heart failure costs at 46B dollars a year, urges therapy optimization
Esperion Therapeutics has estimated the annual economic burden of heart failure in the U.S. to be $46 billion, encompassing healthcare, medications, and lost productivity. The company advocates for optimizing guideline-directed therapy and enhancing patient education to achieve significant cost savings and improved health outcomes. These strategies are presented as both financially beneficial and life-saving for the healthcare system and society.
Drugmaker Esperion gives new hires 260,000 stock units to join
Esperion (NASDAQ: ESPR) has granted 260,000 restricted stock units (RSUs) to 23 new employees under its 2017 Inducement Equity Incentive Plan, adhering to NASDAQ Rule 5635(c)(4). These RSUs will vest 25% after one year and the remaining 75% in twelve quarterly installments, contingent on continued employment. This move aims to attract and retain talent, aligning employee incentives with shareholder interests, though it may incrementally dilute existing shareholders upon vesting.
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion announced it granted 260,000 restricted stock units (RSUs) to 23 new employees on May 12, 2026, under its 2017 Inducement Equity Incentive Plan. These grants are designed to attract new talent as an inducement to employment, aligning with NASDAQ Listing Rules. The RSUs will vest over time, with a portion vesting on the one-year anniversary of the start date and the remainder in quarterly installments, subject to continued employment.
Esperion Therapeutics stock (US2964331002): Archimed acquisition deal closes chapter on independent
Esperion Therapeutics has agreed to be acquired by Archimed for up to $1.1 billion, with shareholders receiving $3.16 per share upfront and potential milestone payments. This transaction, expected to close in Q3 2026, represents a significant premium for Esperion shareholders and will make the company privately held. The deal highlights continued investor interest in cardiovascular therapeutics.
ESPR Stock Surges 44% in a Month: Here's What You Need to Know
Esperion Therapeutics (ESPR) stock has surged nearly 44% in the past month following an announcement that it will be acquired by Archimed for up to $1.1 billion, including potential milestone payments. The transaction offers Esperion shareholders $3.16 per share in cash at closing, plus contingent payments tied to future sales of its key products, Nexletol, Nexlizet, and Enbumyst. The deal is expected to close in the third quarter of 2026, after which Esperion will become a private company.
New cholesterol data in kids and statin-intolerant adults at EAS 2026
Esperion (NASDAQ: ESPR) announced that it will present new analyses and encore presentations on bempedoic acid at the European Atherosclerosis Society (EAS) Congress 2026. This data includes findings from a Phase 2 pediatric study showing LDL-C reductions in children with heterozygous familial hypercholesterolemia (HeFH), supporting advancement to Phase 3 development. Additionally, new analyses from the CLEAR Outcomes trial will identify factors associated with enhanced LDL-C reductions in statin-intolerant adults.
Esperion Therapeutics’ 10-Q Forward-Looking Statements Highlight Significant Uncertainty and Investor Risk
Esperion Therapeutics' latest 10-Q filing contains forward-looking statements that inherently carry significant uncertainty, according to an external analysis. These statements, which cover accounting, financial, and operational projections, are not guarantees, meaning actual results could substantially differ and expose investors to heightened risks. The disclaimer from Esperion Therapeutics suggests considerable variability in its future performance due to internal plans and external economic factors, which could affect company valuation, risk premiums, and stakeholder confidence.
Esperion Therapeutics (ESPR) Q4 Profit Swing Challenges Bearish Earnings Narratives
Esperion Therapeutics (ESPR) reported a significant Q4 2025 profit of US$61.8 million, moving from a loss in the previous quarter, and revenue of US$168.4 million. While bulls highlight this step towards profitability and projected revenue growth, bears point to ongoing trailing losses, negative shareholders' equity, recent shareholder dilution, and insider selling as concerns. The article discusses how these factors influence investor perception and the company's valuation.
Esperion Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Esperion Therapeutics Inc. has released its earnings summary for the quarter that ended on March 31. The report, provided by Refinitiv, gives a brief overview of the company's financial performance. Further details would typically be available upon logging into a TradingView account.
Buyout values Esperion (NASDAQ: ESPR) at $3.16 in cash plus CVR
Esperion Therapeutics reported strong Q1 2026 results with revenue up to $80.1 million and a narrower net loss, driven by product sales and collaboration revenue. The company is set to be acquired by Essence Parent Inc. for $3.16 per share in cash plus one contingent value right (CVR) tied to up to $100 million in future milestone payments, pending stockholder approval. Additionally, Esperion expanded its cardiovascular portfolio with the acquisition of Corstasis and its FDA-approved drug Enbumyst.
Esperion Therapeutics(ESPR) Stock Options Chain | Quotes & News
This article provides stock options chain data, quotes, and news for Esperion Therapeutics (ESPR). It serves as a resource for investors interested in the financial performance and options trading related to the company's stock.
United States - Goodwin Advises Esperion On $1.1 Billion Acquisition By ARCHIMED
Goodwin Procter LLP has advised Esperion Therapeutics on its acquisition by ARCHIMED, a healthcare-focused investment firm. The deal is valued at up to approximately $1.1 billion in total equity, with Esperion shareholders receiving an upfront cash payment of $3.16 per share and potential contingent milestone payments. Esperion, a biopharmaceutical company specializing in cardiometabolic and rare/orphan diseases, focuses on developing and commercializing therapies, including non-statin treatments for LDL-C levels, and is expanding its pipeline.
Esperion Therapeutics (Nasdaq:ESPR) - Stock Analysis
Esperion Therapeutics (ESPR) is a biopharmaceutical company focused on treatments for elevated LDL cholesterol. The company's stock is currently trading below its estimated fair value, with analysts forecasting significant earnings growth. Recent developments include an agreement to be acquired by ArchiMed SAS for approximately $830 million (up to $1.1 billion including milestones) and positive updates on its Vision 2040 plan and product labels.
Esperion Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Esperion Therapeutics, Inc. - ESPR
Kahn Swick & Foti, LLC (KSF) is investigating the proposed sale of Esperion Therapeutics, Inc. (NasdaqGM: ESPR) to ARCHIMED funds. Shareholders are set to receive $3.16 per share in cash plus contingent milestone payments. KSF is scrutinizing whether this consideration is adequate and if the process leading to the sale undervalues the company.
